TNF Inhibitor denied for missing prior authorization by Highmark?

Highmark uses Prime Therapeutics PBM. Adalimumab biosimilar preferred (Cyltezo/Hyrimoz/Yusimry). Step therapy through preferred biosimilar required for new starts; existing patients on Humira may grandfather.

Highmark Continuity of Care provisions — 90-day grandfather for established therapy. Cite Prime Therapeutics PA exception process. ACR 2019 Position Statement opposes non-medical switching of stable patients.

## Why Highmark Requires Prior Authorization for TNF Inhibitors

TNF inhibitors are specialty-tier biologics for which Highmark — like most major insurers — requires prior authorization (PA) before coverage is approved. These drugs are used to treat serious immune-mediated conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Highmark's PA process is designed to confirm that the patient has the appropriate diagnosis, has completed any required step-therapy sequence, and that the prescribing clinician has documented the medical necessity for this drug class.

A denial for "prior authorization required" most commonly means that the PA request was not submitted before the prescription was filled, the PA submission was incomplete, or the PA was denied because it did not meet the criteria Highmark applied at the time of review.

## Why This Denial Is Often Appealable

PA denials are among the most frequently reversed on appeal. The most common reason for reversal is additional documentation that was absent from the original submission. The treating specialist's detailed letter, a complete record of prior therapies, and objective chart evidence of disease severity — organized to map directly onto Highmark's stated PA criteria — address the gaps that most PA denials identify.

## Your Federal Appeal Rights

• Internal appeal: File within the deadline in your denial notice. Highmark must decide pre-service non-urgent appeals within 30 days; urgent pre-service within 72 hours; post-service within 60 days.
• External review (ACA §2719): After the internal process is exhausted, request IRO external review within approximately four months of the final denial. The IRO decision is binding on Highmark.
• Expedited review: Request simultaneously with the internal appeal when delay would seriously jeopardize your health; typically decided within 72 hours.
• ERISA §503: If your plan is employer-sponsored, you have the right to a full-and-fair review, access to all documents used in Highmark's decision, and the opportunity to submit evidence.

## Documentation to Gather

1. Diagnosis documentation — chart notes, specialist records, lab results, and imaging confirming the diagnosis with the ICD code that maps to an FDA-approved indication for the prescribed TNF inhibitor. 2. Disease-severity records — objective clinical findings documenting the severity of the condition, consistent with the level required by Highmark's PA criteria for biologic therapy. 3. Prior-treatment history — a dated, comprehensive list of previously tried therapies with outcomes, covering any step-therapy requirements in Highmark's PA policy. 4. Prescriber medical-necessity letter — a letter from the treating specialist that addresses each of Highmark's PA criteria explicitly, documents the clinical rationale, and confirms the patient's eligibility for this drug class. 5. Highmark's current PA criteria — obtain the most recent version of the TNF inhibitor medical policy from highmarkbcbs.com to ensure the appeal responds to every stated requirement.

## Criteria-Mapping Strategy

Print Highmark's current PA criteria and work through each requirement with the prescriber. For every criterion, identify the specific chart note, lab result, or dated record that satisfies it. Organize the appeal package with a cover table that lists each criterion and the exhibit satisfying it, followed by the supporting documents. This structure forces a line-by-line review rather than a summary judgment, and it gives the appeals nurse reviewer and any external IRO reviewer a clear, verifiable record on which to base approval.